Loading clinical trials...
Loading clinical trials...
Cannabinoid Analgesia for Medical Abortion: A Randomized Controlled Trial
The objective of this study is to determine if a synthetic cannabis derivative, dronabinol, in addition to ibuprofen, decreases maximum pain scores compared to ibuprofen and placebo in women undergoing medical abortion. Results of this study will help providers counsel patients regarding cannabis use during medical abortion.
This is a randomized, double-blind, placebo-controlled trial comparing pain levels in women undergoing medical abortion with one of two regimens: ibuprofen 800mg and a 5mg oral dronabinol versus ibuprofen 800mg and placebo given at the time of misoprostol administration. This study will include 62 women undergoing medical abortion. Women will be randomized to dronabinol 5mg oral versus placebo. The primary outcome will be maximum reported pain score within 24 hours of misoprostol administration.
Age
21 - 89 years
Sex
FEMALE
Healthy Volunteers
No
Oregon Health & Science University
Portland, Oregon, United States
Start Date
November 1, 2018
Primary Completion Date
May 7, 2019
Completion Date
May 28, 2019
Last Updated
April 7, 2020
72
ACTUAL participants
Dronabinol 5mg Cap
DRUG
Placebo
OTHER
Lead Sponsor
Oregon Health and Science University
Collaborators
NCT06346132
NCT07482709
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07351968